Navigation path


Targeting assembly of infectious HIV particles
Framework programme:
Contract/Grant agreement number:
EC contribution:
3.000.000 €
36 months
Funding scheme:
Collaborative Project
Starting date:

Keywords: AIDS/HIV, capsid assembly, Env incorporation, antiretrovirals, screening, HIV budding, medicinal chemistry, virology, cell biology, drug discovery, drug development


AIDS is one of the major life threatening infectious diseases in the world today. A constant supply of novel antiretrovirals (ARVs) is needed to respond to the limitations of current drugs. The currently available therapeutic arsenal against HIV comprises ARVs which block all major steps of HIV replication, except for particle assembly and budding.

Combinations of the currently available anti-viral drugs within highly active anti-retroviral therapy (HAART) have transformed the course of HIV infection into a chronic disease, but even so, HAART faces three major limitations: viral resistance, viral persistence, and drug toxicity. There is a consensus that a constant supply of new antiretroviral molecules based on novel mechanisms of action is needed to respond to the major limitations of drugs currently available.

HIV-ACE is composed of 8 teams from 5 European countries including a Biopharma small to medium-sized enterprise (SME), CellVir. These laboratories are led by prominent world-class scientists in virology, cell biology, immunology, organic and medicinal chemistry, working in highly regarded research organisations. To efficiently achieve the ambitious goals of HIV-ACE, strong management is led by a very experienced organisation, INSERM Transfert.

[+] Read More